Here are four quick facts:
1. Two analysts granted the shares a “buy” rating.
2. One analyst gave the shares an “outperform” rating, and another analyst gave the shares a “underperform” rating.
3. In August 2015, Jefferies analysts reiterated Orthofix International shares’ “buy” rating.
4. Jefferies has a $48 price target on Orthofix stock.
More articles on devices:
CTL Medical Corporation acquires nationally recognized medical device company, AccelSPINE
BionX Medical Technologies raises $17M in series E funding: 4 things to know
Stryker names Gary Boehnlein next VP, CFO — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
